March 14, 2024 05:34 AM EDTUpdated 06:39 AM
People
R&D

Spruce Bio­sciences’ stock plum­mets in wake of PhI­Ib flop, biotech to cut staff

Reynald Castañeda

Deputy Editor

Amber Tong

Spruce Bio­sciences’ tildac­er­font failed a Phase IIb test in adults with con­gen­i­tal adren­al hy­per­pla­sia (CAH) due to com­pli­ance is­sues, crush­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times